Precigen, Inc. (PGEN)
| Market Cap | 296.21M |
| Revenue (ttm) | 6.76M |
| Net Income (ttm) | -85.02M |
| Shares Out | 248.92M |
| EPS (ttm) | -0.37 |
| PE Ratio | n/a |
| Forward PE | 6.27 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,121,790 |
| Open | 1.14 |
| Previous Close | 1.12 |
| Day's Range | 1.10 - 1.20 |
| 52-Week Range | 0.81 - 2.29 |
| Beta | 1.86 |
| Analysts | Buy |
| Price Target | 10.00 (+740.34%) |
| Earnings Date | Nov 9, 2023 |
About PGEN
Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. The company operates through two segments, Biopharmaceuticals and Exemplar. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; and reproductive technologies. In addition, the company offers UltraVector platform that incorporates advanced DNA construction technologies and computational models to design and assemble genetic components into complex gene expression programs... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for PGEN stock is "Buy." The 12-month stock price forecast is $10.0, which is an increase of 740.34% from the latest price.
News
Precigen to Participate in the JMP Securities Hematology and Oncology Summit
GERMANTOWN, Md. , Nov. 29, 2023 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of...
Precigen Reports Third Quarter 2023 Financial Results and Progress of Clinical Programs
– Based on FDA confirmation in August 2023 that the ongoing Phase 1/2 single-arm study of PRGN-2012 in RRP will serve as the pivotal study to support BLA submission under an accelerated approval req...
Precigen to Participate in the Stifel 2023 Healthcare Conference
GERMANTOWN, Md. , Nov. 7, 2023 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of ...
Precigen to Participate in Upcoming Leading Investor and Industry Conferences
GERMANTOWN, Md. , Sept. 19, 2023 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives o...
Precigen Reports Second Quarter and First Half 2023 Financial Results and Provides Update on Portfolio Prioritization and Capital Allocation Strategies to Extend Projected Cash Runway into 2025
– The FDA confirmed that the ongoing Phase 1/2 single arm study of PRGN-2012 in RRP will serve as the pivotal study to support accelerated approval and no additional randomized, placebo-controlled t...
Precigen Announces FDA Confirmation that the Ongoing Phase 1/2 Study of PRGN-2012 AdenoVerse Immunotherapy Will Serve as the Pivotal Study to Support Accelerated Approval
– FDA confirmed that the ongoing Phase 1/2 single arm study will serve as pivotal and no additional randomized, placebo-controlled trial will be required to support submission of a BLA – – FDA a...
Precigen to Announce Second Quarter and First Half 2023 Financial Results on August 9th
GERMANTOWN, Md. , Aug. 3, 2023 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of ...
Precigen Receives Breakthrough Therapy Designation for PRGN-2012 AdenoVerse™ Immunotherapy for the Treatment of Recurrent Respiratory Papillomatosis
– First FDA Breakthrough Therapy Designation granted for AdenoVerse immunotherapy platform; designation prioritizes PRGN-2012 as a potential treatment for RRP – – Designation based on positive Phase...
Precigen Announces Positive Phase 1 Data for PRGN-3005 Autologous UltraCAR-T® Cells Manufactured Overnight for Infusion Next Day to Advanced Stage Platinum Resistant Ovarian Cancer Patients
– PRGN-3005 was well-tolerated with no dose limiting toxicities, no CRS greater than Grade 2, and no neurotoxicity – – PRGN-3005 cells demonstrated expansion and persistence when delivered via either ...
Precigen Announces Positive Phase 1 Data for Off-the-Shelf PRGN-2009 AdenoVerse™ Immunotherapy Alone and in Combination with an Investigational Checkpoint Inhibitor in Patients with Recurrent/Metastatic HPV-associated Cancers
– PRGN-2009 combined with an investigational checkpoint inhibitor resulted in a 30% ORR in patients with heavily pre-treated HPV-associated cancers that were naïve or resistant to checkpoint blockade...
Precigen Receives FDA Clearance of IND to Initiate Phase 2 Study of PRGN-2009 Off-the-Shelf AdenoVerse Immunotherapy in Combination with Pembrolizumab to Treat Patients with Recurrent or Metastatic Cervical Cancer
– HPV is responsible for more than 90 percent of cervical cancer cases globally with approximately 300,000 women living with cervical cancer in the US – – Current response rates to second line treat...
Precigen Reports First Quarter 2023 Financial Results and Business Updates
– Positive Phase 1 clinical data presented for PRGN-2012 AdenoVerse ™ immunotherapy in RRP demonstrated favorable safety profile and significant reduction in surgeries with 50% of the patients in C...
Precigen to Announce First Quarter 2023 Financial Results on May 10th
GERMANTOWN, Md. , May 3, 2023 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of p...
Precigen to Present Latest Clinical Advancements for PRGN-3005 UltraCAR-T® and PRGN-2009 Off-the-Shelf AdenoVerse™ Immunotherapy at the 2023 ASCO Annual Meeting
GERMANTOWN, Md. , April 26, 2023 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives o...
Precigen Presents Preclinical Data for the Next Generation Mesothelin UltraCAR-T® with Intrinsic PD-1 Blockade at the AACR Annual Meeting 2023
GERMANTOWN, Md., April 17, 2023 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of...
Precigen Regains Exclusive Rights to Proven CAR-T Targets, CD19 and BCMA, to Enable Unencumbered Development and Commercialization of UltraCAR-T®
– Precigen amends exclusive license agreement with Alaunos to bolster portfolio and broaden strategic opportunities – – The Company also regains exclusive rights to IL-12 gene therapy, including ap...
Precigen Announces Further Advancement of UltraCAR-T® Platform with First Patient Dosed in Phase 1/1b Dose Escalation/Dose Expansion Study of PRGN-3007 in Advanced ROR1+ Hematological and Solid Tumors
– Milestone represents the first patient dosed with the next generation UltraCAR-T, incorporating PD-1 checkpoint inhibition in addition to three effector genes – – Proprietary technology for checkpoi...
Precigen to Participate in a Virtual Fireside Chat at Cantor's "The Future of Oncology" Virtual Symposium
GERMANTOWN, Md. , March 28, 2023 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives o...
Precigen Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates
– Achieved significant clinical progress for UltraCAR-T ® and AdenoVerse ™ investigational therapeutics in 2022 – – Presented positive clinical data for PRGN-2012 AdenoVerse immunotherapy in recurr...
Precigen Announces Closing of Public Offering of Common Stock
GERMANTOWN, Md. , Jan. 27, 2023 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN) announced today the closing of its previously announced underwritten public offering of common stock.
Precigen Announces Pricing of $75.0 Million Public Offering of Common Stock
GERMANTOWN, Md. , Jan. 24, 2023 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN) today announced the pricing of an underwritten public offering of 42,857,143 shares of its common stock at a public offeri...
Precigen Announces Proposed $75.0 Million Public Offering of Common Stock
GERMANTOWN, Md. , Jan. 24, 2023 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN) today announced it has commenced an underwritten public offering of $75.0 million of its common stock.
Precigen Announces Positive Phase 1 Dose Escalation and Expansion Cohort Data for Investigational Off-the-Shelf PRGN-2012 AdenoVerse™ Immunotherapy in Patients with Recurrent Respiratory Papillomatosis
– Repeated administrations of PRGN-2012 were well-tolerated with no dose-limiting toxicities and no treatment-related adverse events greater than Grade 2 – – Clinical data show strong response in RR...
Precigen Provides Pipeline and Corporate Updates at the 41st Annual J.P. Morgan Healthcare Conference
– Company achieved significant progress for its clinical pipeline in 2022 – – Precigen to host R&D Day virtual event on January 24, 2023, at 4:30 PM ET to share safety and efficacy data from the Ph...
Precigen to Host a Virtual R&D Event on January 24th to Share Safety and Efficacy Data from the Phase 1 Dose Escalation and Expansion Cohorts of PRGN-2012 AdenoVerse™ Immunotherapy in Recurrent Respiratory Papillomatosis
GERMANTOWN, Md. , Jan. 4, 2023 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of ...